Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO), established in 1994. Over the years, we have developed an expertise in the development and manufacturing of non-sterile liquids, suspensions, and semi-solid drug products. This strategic focus has allowed us to establish a unique expertise to support your product development and manufacturing needs, which, combined to our operational flexibility and commitment to delivering on time, enables us to operate as an extension of your team. Our business is 100% fee-for-service and exclusively focused on contract services. We are here to help you meet your company objectives, not to compete with you. | Groupe PARIMA is a leading Contract Development & Manufacturing Organization (CDMO) that excels in the development and manufacturing of non-sterile pharmaceutical products. Specializing in liquids, semi-solids, and suspensions, we offer an extensive range of services focused on product development, commercial manufacturing, packaging and laboratory testing. Our modern facility is equipped to handle complex pharmaceutical formulations and packaging requirements. At the core of our operation is a deep commitment to research and development. Our expert team collaborates closely with clients to design and optimize formulations that meet specific patient needs, ensuring each product achieves optimal effectiveness and regulatory approval. This focus on development is complemented by our flexibility to scale processes seamlessly from pilot batches to clinical supply and eventually large-scale commercial production. Our team of skilled professionals bring a wealth of industry knowledge and technical expertise, making us a preferred partner for both emerging biotechs and established pharmaceutical companies across 28 countries. Groupe PARIMA’s ability to adapt swiftly to changing market conditions and client requirements sets us apart in the dynamic pharmaceutical landscape. With ample manufacturing capacity and comprehensive on-site services including laboratory testing and regulatory compliance activities, we are equipped to handle diverse project demands with precision. Whether advancing a novel treatment or expanding production capabilities, Groupe PARIMA provides the expertise and infrastructure necessary to bring your pharmaceutical products to global markets. Explore the possibilities with Groupe PARIMA as your dedicated CDMO partner. Discover our full range of development capabilities and services at www.groupeparima.com. | Groupe PARIMA, a CDMO since 1994, specializes in the development and manufacturing of non-sterile liquids, suspensions, and semi-solids. With deep expertise in complex formulations, scale-up, and regulatory compliance, we provide end-to-end support from development to commercial production. Our flexible approach, technical proficiency, and commitment to on-time delivery make us a trusted partner for pharmaceutical companies worldwide. As a dedicated contract service provider, we focus entirely on supporting our clients’ success with tailored solutions and operational agility.
Government of Tamil Nadu – Guidance & TICEL Bio Park Limited
Guidance TamilNadu Guidance Tamil Nadu is the investment promotion agency of the Government of Tamil Nadu, India’s most industrialized state. With a robust and diverse industrial ecosystem, Tamil Nadu is advancing its biotechnology sector with a focused, mission-driven approach. As a single-window facilitation body, Guidance offers end-to-end support to investors through a dedicated team of sector specialists, policy advisors, and international consultants. We streamline the investment journey by coordinating with industry stakeholders, community partners, and government departments—consolidating efforts to ensure a seamless and efficient business experience. In the life sciences sector, Guidance’s primary objective is to position Tamil Nadu as the investment destination of choice. This is achieved by enhancing ease of doing business, reducing operational costs, enabling policy frameworks tailored to the evolving global life sciences landscape, and providing sustained, expert-backed support throughout the investment lifecycle. TICEL Biopark Limited TICEL Biopark Limited, Chennai, Tamil Nadu, India is a state – of – art Biotechnology Park established in 2004 in Tamil Nadu, India. TICEL Biopark is promoted by TIDCO (Tamil Nadu Industrial Development Corporation) in technical collaboration with Cornell University, USA. TICEL Biopark supports Biotech ecosystem from their early stage of research to pilot-scale production by providing laboratory infrastructure and equipment support. Major companies such as Biocon biologics, Teva pharma, Levim biotech, Amway, Johnson & Johnson, Hiyoshi India and Revvity Health sciences are located in Ticel Bio Park. The Biotech Core Instrumentation Facility, housed at TICEL Biopark, provides equipment support to startups and industries. TICEL provides Laboratory infrastructure which supports to create GMP/GLP/ Contract Research (CRO) / Contract Manufacturing (CMO) / testing facility. TICEL infrastructure includes utilities such as RO water plant, Gas Bank, Vacuum air, Compressed air, Fume hood exhaust with scrubber, HVAC system, Bio waste disposal, STP & ETP plant etc. TICEL supports startups/Industries by providing equipment, incubation space, and resources to conduct research and commercialize their products. TICEL also conducts skill development programs and hands-on workshops for students and scientific professionals. Additionally, TICEL undertakes contract research and contract manufacturing work at its Biotech Core Instrumentation Facility.
Galenvs Sciences
Galenvs couples precision magnetic-nanoparticle synthesis with advanced oligonucleotide chemistry— under ISO 9001 — to accelerate diagnostic, therapeutic product development. We engage projects from lead candidate optimization through rapid synthesis, purification, QA/QC, and pilot batches in weeks instead of months, and routinely supply complex siRNA, sgRNA, ASO, Aptamers, and other heavily modified oligos at ≥95 % yield. Our proprietary nanoparticles, tunable for size, coating, and functionality, deliver
Fondazione Ri.MED
The Ri.MED Foundation develops innovative biotechnology and biomedical research aimed at timely transferring scientific discoveries in clinical practice. Ri.MED was established as an international partnership between Italian Government, Italian National Research Council (CNR), Region of Sicily, University of Pittsburgh, and UPMC. In 2017, Ri.MED entered the governance of the transplant-specialized hospital ISMETT, to create an integrated translational research and highly specialized care cluster, with the goal to rapidly transfer scientific results “from bench to bedside”. The Foundation is engaged in training highly qualified staff, disseminating scientific knowledge, and establishing and managing research centers and laboratories. Consistently with its mission, the Ri.MED Foundation has achieved important results, training several biotechnology professionals, publishing hundreds of scientific articles, generating intellectual property covered with filed patents (31 today), and promoting local scientific and public engagement events. Ri.MED manages laboratories in Sicily and, at the same time, is designing the Biomedical Research and Biotechnology Center (“BRBC”) that it is actually under construction near Palermo. The result of this strategy will foster innovative solutions for patients, and an increased ability to attract new funds. Ri.MED research stems from medical need to develop innovative solutions, and focuses on four main therapeutic areas: cancer, with special focus on immunotherapy; organ failure, including organ transplantation and regenerative medicine; infectious diseases; and aging-associated diseases, with a focus on neurodegeneration. Ri.MED’s scientific projects are based on three main areas of interest: regenerative medicine and immunotherapy, aimed at developing advanced therapy medicinal products (ATMP); new drug discovery research and development; and tissue engineering and biomedical bioengineering, focused on developing biomaterials, engineered tissues, and medical devices. The activities range from identifying new biologically active molecules to developing cellular products for tissue repair and/or regeneration, and organotypic cultures for regenerative purposes and as models for pharmacology screening, and all the way to simulation of physiological systems and preclinical validation of new generation implantable organs and devices. Ri.MED has a diversified and balanced project portfolio led by a multidisciplinary team with clear product development goals and a “bench-to-bedside” approach. The translational research engine of Ri.MED Foundation envisages the development of 10 skills and technology platforms supporting scientific projects: Biophysics and Structural Biology, High Throughput Screening, Bioinformatics and Molecular Informatics, Advanced Data Analysis, Biomedical Imaging and Radiomics, Proteomics, Cell factory for the production of ATMP, Medicinal Chemistry, Bioengineering and Tissue Engineering. Scientific dissemination and sharing research outcomes are part of the Foundation’s mission. This involves developing a wide network of collaborations and scientific agreements with institutions in strategic areas of interest: 16 new agreements in 2022. Training highly qualified personnel is not only part of Ri.MED’s mission, but a task the Foundation carries out with particular enthusiasm, understanding that offering high-level training can contribute to enriching the future of young people, and the competitiveness and development of Sicily. | The Foundation, based in Palermo, promotes, supports and leads biomedical and biotechnological research projects, with emphasis on the translation of innovative results into clinical practice. Ri.MED is currently focused on the creation of the Biomedical Research and Biotechnology Centre, which will be a reference point for researchers from all over the world. At the same time, the Foundation trains the researchers who will provide the human capital of the Research Centre. In preclinical and clinical research, strategic are the partnerships with the University of Pittsburgh, UPMC and IRCCS-ISMETT, which have yielded proprietary intellectual property resulting in several joint patent applications. The generation of intellectual property represents a fundamental intangible asset in the valorization of the Fondazione Ri.MED, with the perspective of developing an innovative model of sustainable research.
Finao Biotech
FINAO Biotech is a pharmaceutical company specializing in biotechnology, based in Rio de Janeiro, Brazil with global reach. Our goal is to serve, to improve the quality of life of our customers through a range of innovative products based on sustainable development, production, distribution and commercialization of medicines, innovative medical devices, cosmetics, food supplements and veterinary. At FINAO Biotech we care about society and the environment. Our innovative medical products, highly efficient, reflect our concerns and represent our strength in doing more and better, combining technology with the environment and society. Words like efficiency and sustainability have accompanied our company. The search for the best pharmaceutical development solutions has made FINAO Biotech’s portfolio broader, with a range of innovative products.
FeroptoCure Inc
FerroptoCure Inc. is at the forefront of developing revolutionary anticancer drugs that leverage ferroptosis, a novel form of cell death induced by oxidative stress. The suppression of ferroptosis is closely linked to the onset, growth, and spread of various cancers, as well as the development of resistance to conventional anticancer treatments. This makes ferroptosis a critical and promising target for next-generation cancer therapies. Our innovative approach focuses on disrupting the anti oxidative systemin which suppress ferroptosis in cancer. This allows us to target cancer cells with unprecedented precision and efficacy. By addressing this mechanism, our drugs have the potential to treat a wide range of cancers, including those that are resistant to current therapies. Our anti-cancer drugs have demonstrated anti-tumor effects in various types of cancer and holds great promise as a highly valuable advancement. Furthermore, our approach involves the use of small molecule compounds, which eliminates the need for specialized and costly techniques. These offer hope to patients with limited treatment options. FerroptoCure has already entered the Phase I clinical trial mainly targeting triple-negative breast cancer, a significant milestone that underscores the potential of our drug candidates to transform the oncology landscape. By combining cutting-edge science with a commitment to improving patient outcomes, we aim to deliver groundbreaking solutions that bring significant innovation to cancer treatment. Based on the results of our ongoing trials, we are prepared to rapidly expand development on a global scale, targeting not only Japan but global market. The market potential for our ferroptosis-based therapy is enormous. The global oncology drug market is expected to surpass $500 billion by 2030, with hard-to-treat cancers representing a significant share. The TNBC market alone is projected to exceed $3 billion by 2027, and by expanding our approach to broader indications, FerroptoCure has the potential to capture a 200 billion-dollar market worldwide. With global clinical trials planned, we are actively securing **regulatory approvals (FDA/EMA) and strategic partnerships. Backed by cutting-edge science, FerroptoCure is set to redefine cancer treatment and bring a breakthrough cure to patients worldwide.
FAREVA
Farera as a CDMO is providing a large service offer as sterile injectable and high potent, biological drug, conventionnal product, medial devices, foods supllements and probiotics as well as Drug substance manufacturing of recombinant protein, Andibody Dug Conjugason (ADC) with the associated Fill& Finish | FAREVA is a leading global pharmaceutical CDMO with industry leading capabilities in the development and manufacturing of a large range of Drug Products and Active Pharmaceutical Ingredients (APIs). FAREVA employs 13,000 people distributed in 41 production sites located in 13 countries in EMEA and the Americas. 16 of the FAREVA sites are dedicated to pharmaceutical activities. FAREVA’s API division has operations in 3 European sites located in France and Germany. | Fareva is a leading global pharmaceutical CDMO with a network of 16 manufacturing sites and 3 development sites throughout EMEA and the Americans. We offer comprehensive drug product and API services, including formulation development, clinical manufacturing, scale-up, and commercial manufacturing of small and large molecules. Our capabilities cover a wide range of dosage forms, such as OTC products, oral solid doses, non-sterile liquids and solids, ophthalmics, as well as sterile fill/finish and lyophilized presentations. In addition, our facilities have extensive expertise in secondary packaging, enabling us to serve as a fully integrated partner for our clients’ end-to-end pharmaceutical needs.
Eurogentec
Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010. Headquartered in Liege (Belgium) it provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments. Eurogentec has production sites in Europe and United States of America. The company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines). | Founded in 1985 and part of Kaneka Corporation since 2010, Eurogentec is a leading biotechnology and CDMO company specializing in GMP-certified manufacturing of starting materials and APIs. With facilities in Europe and the USA, we support plasmid DNA, mRNA, recombinant proteins, peptides, antibody fragments, and therapeutic oligonucleotides from early research to clinical and commercial production. Our expertise in process development and scale-up ensures high-quality solutions at every stage. Detailed Description of Products (Event Specific) max 500 characters in English – Plasmid DNA : Starting material & APIs including Nano-plasmids & Minicircle DNA. FastTrack: 4-month production. – mRNA : IVT mRNA (0.1g–50g), saRNA, gRNA with co-/post-transcriptional modifications. – Proteins : GMP production in E. coli & P. pastoris for biotech & pharma. – Conjugates : Chemically modified recombinant proteins for clinical use. – Therapeutic Oligos : ASOs, siRNA, aptamers, CpG oligos. – Peptides : Linear, cyclic & complex-modified. – Antibody Fragments : scFv, Fab, VHH, bispecifics. | Eurogentec—part of Kaneka Corp. since 2010—is a leading international company founded in 1985 and headquartered in Belgium. Accredited by the Belgian AFMPS, US FDA, and Japanese MHLW, we deliver trusted solutions to the life sciences, molecular diagnostics, and therapeutic development sectors. As a major supplier in genomics (oligonucleotides, qPCR kits, reagents) and proteomics (custom and catalog antibodies, peptides), we also act as a reliable CDMO for process development and GMP manufacturing of vaccines and medicines—including therapeutic oligonucleotides, peptides, plasmids, recombinant proteins, mRNA and VHH antibodies. Our comprehensive services cover process transfer, development and optimization, scale-up, tox and clinical batches, GMP and GMP-like manufacturing, Quality Control, QA release, and ICH stability studies. From early-phase development to commercialization, Eurogentec is your single partner for every step of the journey.